ID
34754
Description
Vildagliptin Veresus Liraglutide - Patient Preference After Receiving Both Medications; ODM derived from: https://clinicaltrials.gov/show/NCT01518101
Link
https://clinicaltrials.gov/show/NCT01518101
Keywords
Versions (1)
- 1/26/19 1/26/19 -
Copyright Holder
See clinicaltrials.gov
Uploaded on
January 26, 2019
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Eligibility Type 2 Diabetes NCT01518101
Eligibility Type 2 Diabetes NCT01518101
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
Acute Disease
Data type
boolean
Alias
- UMLS CUI [1]
- C0001314
Description
Kidney Diseases | Creatinine measurement, serum | Glomerular Filtration Rate
Data type
boolean
Alias
- UMLS CUI [1]
- C0022658
- UMLS CUI [2]
- C0201976
- UMLS CUI [3]
- C0017654
Description
Medical contraindication Gliptins | Medical contraindication Glucagon-Like Peptide Analogue
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1301624
- UMLS CUI [1,2]
- C1827106
- UMLS CUI [2,1]
- C1301624
- UMLS CUI [2,2]
- C0014361
- UMLS CUI [2,3]
- C0243071
Description
Dipeptidyl-Peptidase IV Inhibitors | GLP-1 Mimetics
Data type
boolean
Alias
- UMLS CUI [1]
- C1827106
- UMLS CUI [2]
- C3273809
Description
Eligibility Criteria Study Protocol
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1516637
- UMLS CUI [1,2]
- C2348563
Similar models
Eligibility Type 2 Diabetes NCT01518101
- StudyEvent: Eligibility
C0201976 (UMLS CUI [2])
C0017654 (UMLS CUI [3])
C1827106 (UMLS CUI [1,2])
C1301624 (UMLS CUI [2,1])
C0014361 (UMLS CUI [2,2])
C0243071 (UMLS CUI [2,3])
C3273809 (UMLS CUI [2])
C2348563 (UMLS CUI [1,2])